PAMP
DNLI icon

Polar Asset Management Partners’s Denali Therapeutics DNLI Stock Holding History

Polar Asset Management Partners’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-91,600
Closed -$1.28M – 713
2025
Q2 		$1.28M Buy
91,600
+70,648
+337% +$994K 0.02% 344
2025
Q1 		$285K Sell
20,952
-530,140
-96% -$10.2M 0.01% 355
2024
Q4 		$11.2M Buy
551,092
+509,992
+1,241% +$13.1M 0.13% 142
2024
Q3 		$1.2M Buy
41,100
+17,000
+71% +$421K 0.03% 393
2024
Q2 		$560K Buy
+24,100
New +$463K 0.01% 423

Other funds holding DNLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Polar Asset Management Partners's DNLI Position: Q3 2025 in Review

Polar Asset Management Partners sold out of Denali Therapeutics (DNLI) in Q3 2025, closing a stake of 91,600 shares — an estimated $1.28M sold.

Polar Asset Management Partners first reported a position in DNLI in Q2 2024 and held it in 5 quarters. The position peaked at $11.2M in Q4 2024. 240 funds tracked by Wall St. Rank hold DNLI as of Q3 2025.

  • Polar Asset Management Partners reported no remaining Denali Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Polar Asset Management Partners sold 91,600 Denali Therapeutics shares in Q3 2025, an estimated $1.28M.
  • Polar Asset Management Partners first reported a position in Denali Therapeutics in Q2 2024 and held it in 5 quarters.
  • Polar Asset Management Partners's Denali Therapeutics position peaked at $11.2M in Q4 2024.
  • 240 funds tracked by Wall St. Rank held Denali Therapeutics as of Q3 2025.

Based on Polar Asset Management Partners's 13F filing for Q3 2025, filed 14 Nov 2025.